Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson’s Disease: An Analysis of NET-PD LS1

Background: Monoamine oxidase type B (MAO-B) inhibitors exhibit neuroprotective effects in preclinical models of PD but clinical trials have failed to convincingly demonstrate disease modifying benefits in PD patients. Objective: To perform a secondary analysis of NET-PD LS1 to determine if longer d...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Robert A. Hauser, Ruosha Li, Adriana Pérez, Xuehan Ren, Dan Weintraub, Jordan Elm, John L. Goudreau, John C. Morgan, John Y. Fang, Michael J. Aminoff, Chadwick W. Christine, Rohit Dhall, Chizoba C. Umeh, James T. Boyd, Natividad Stover, Maureen Leehey, Richard M. Zweig, Anthony P. Nicholas, Ivan Bodis-Wollner, Allison Willis, Karl Kieburtz, Barbara C. Tilley
Format:	Artigo
Język:	Inglês
Wydane:	SAGE Publishing 2017-02-01
Seria:	Journal of Parkinson’s Disease
Dostęp online:	https://doi.org/10.3233/JPD-160965
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!